AbbVievsMoonLake Immunotherapeutics

ABBV and MLTX stock compared: price, dividend, valuation and results, from SEC filings.

MLTX

MoonLake Immunotherapeutics

$11.07

Value $942M

+0.36%
MLTX's page

AbbVie (ABBV) has a market value of $506B and MoonLake Immunotherapeutics (MLTX) $942M. Over the last year, with dividends, ABBV moved +26.6% and MLTX -18.2%. Dividend yield: ABBV 2.42%, MLTX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$506B

    MLTX$942M

    ABBV is 537 times MLTX

  • Revenue, 12 months

    ABBV$66.0B

    MLTX–

  • Net income, 12 months

    ABBV$10.3B

    MLTX-$273M

  • Operating margin

    ABBV32.2%

    MLTX–

  • ROIC

    ABBV25.7%

    MLTX-51.1%

    76.8 points apart

  • P/E

    ABBV49.2

    MLTX–

  • Dividend yield

    ABBV2.4%

    MLTX0.0%

    2.4 points apart

  • 5-year return

    ABBV+194.4%

    MLTX+11.6%

    182.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+194.4%

MLTX+11.6%

20040060020222023202420252026
Returns by period
PeriodABBVWith dividendsMLTXWith dividends
1 year since November 19, 2025+26.6%Price +22.9%-18.2%Price -18.2%
3 years since November 20, 2023+128.8%+31.8% a yearPrice +106.9%-74.1%-36.2% a yearPrice -74.1%
5 years since November 19, 2021+194.4%+24.1% a yearPrice +146.2%+11.6%+2.2% a yearPrice +11.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieMLTXMoonLake Immunotherapeutics

Valuation

ABBVMLTX
Valuation
Price$286.20$11.07
Market value$506B$942M
Enterprise value (EV)$576B$544M
P/E49.2–
P/E, 5-year median57.0–
P/B–2.5
EV/EBIT27.1–
Free cash flow yield3.7%–

Results and growth

ABBVMLTX
Results and growth
Revenue, 12 months$66.0B–
Net income, 12 months$10.3B-$273M
Free cash flow, 12 months$18.9B-$244M
Earnings per share, 12 months$5.81-$3.67
Revenue growth, year on year8.6%–
Revenue growth a year, past+5.9%over 5 years–
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVMLTX
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%–
Net margin15.7%–
ROIC25.7%-51.1%
ROE–-82.5%

Balance sheet

ABBVMLTX
Balance sheet
Cash$10.8B$499M
Total debt$80.9B$102M
Net debt / EBITDA3.2–
Interest cover7.1×-25.6×

Dividends and buybacks

ABBVMLTX
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or MLTX

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or MoonLake Immunotherapeutics?

By market value, AbbVie ($506B) is about 537.1 times MoonLake Immunotherapeutics ($942M), at today's prices.

How did ABBV and MLTX stock do over the last 5 years?

Since November 19, 2021, ABBV's price moved +146.2% and MLTX's +11.6%. With dividends: ABBV +194.4% (+24.1% a year), MLTX +11.6% (+2.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or MLTX?

The dividend yield at today's price is 2.42% for AbbVie and none for MoonLake Immunotherapeutics. Over the last twelve months they paid $6.92 and – per share.

Which is the better investment, AbbVie or MoonLake Immunotherapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.